We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Abbott Laboratories, Boeing, Diageo, Lam Research and Freeport-McMoRan
Read MoreHide Full Article
For Immediate Release
Chicago, IL – February 10, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Abbott Laboratories (ABT - Free Report) , The Boeing Company (BA - Free Report) , Diageo plc (DEO - Free Report) , Lam Research Corp. (LRCX - Free Report) and Freeport-McMoRan Inc. (FCX - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Analyst Reports for Abbott Labs, Boeing and Diageo
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories, The Boeing Company and Diageo plc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Abbott Laboratories have declined -13.7% over the past year against the Zacks Medical - Products industry’s decline of -37.7%. The company’s numbers declined on a year-over-year basis in the latest quarterly release, with sales were negatively impacted by a decline in COVID testing-related sales. Moreover, the decline in U.S. infant formula sales due to manufacturing disruptions dented the quarter’s sales further.
However, Abbott exited the fourth quarter of 2022 with better-than-expected earnings and revenues. Excluding COVID testing sales, worldwide Diagnostics sales grew over 11% led by rapid diagnostics. Within EPD, sales increased 8% organically in the fourth quarter led by double-digit growth across several countries.
Meanwhile, the Diabetes Care business continued to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Shares of Boeing have declined -2.4% over the past year against the Zacks Aerospace - Defense industry’s decline of -7.4%. The company’s 737 MAX program remains a cause of concern in China, thus impacting its expectation of delivery timing and future gradual production rate increases.
Its arch-rival, Airbus, remained quite a step ahead in terms of commercial deliveries during the fourth quarter of 2022. The Russia-Ukraine crisis poses risk for Boeing. However, Boeing remains the largest aircraft manufacturer in the United States, in terms of revenue, orders and deliveries.
Lately, the company has been witnessing solid recovery in its commercial business. The outlook for its defense business also remains optimistic. It holds a strong solvency position in the near term.
Diageo shares have underperformed the Zacks Beverages - Alcohol industry over the past year (-15.6% vs. -9.5%). The company is facing continued inflationary pressures from increased glass, ocean freight and other transportation costs, and currency headwinds are concerning.
Nevertheless, Diageo’s organic operating margin expansion, productivity savings and favorable currency impact aided Diageo’s first-half fiscal 2023 results. Effective marketing and exceptional commercial execution further aided the results. Price/mix gained from a positive mix due to the robust growth in super-premium-plus brands, particularly scotch, tequila and Chinese white spirits.
DEO’s margin trends were favorable in the first half, thanks to the its premiumization efforts, recovery in markets, pricing actions and supply productivity savings, which mostly offset the cost inflation. The company retained its optimistic view for the medium to long term.
Other noteworthy reports we are featuring today include Lam Research Corp. and Freeport-McMoRan Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Abbott Laboratories, Boeing, Diageo, Lam Research and Freeport-McMoRan
For Immediate Release
Chicago, IL – February 10, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Abbott Laboratories (ABT - Free Report) , The Boeing Company (BA - Free Report) , Diageo plc (DEO - Free Report) , Lam Research Corp. (LRCX - Free Report) and Freeport-McMoRan Inc. (FCX - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Analyst Reports for Abbott Labs, Boeing and Diageo
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories, The Boeing Company and Diageo plc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Abbott Laboratories have declined -13.7% over the past year against the Zacks Medical - Products industry’s decline of -37.7%. The company’s numbers declined on a year-over-year basis in the latest quarterly release, with sales were negatively impacted by a decline in COVID testing-related sales. Moreover, the decline in U.S. infant formula sales due to manufacturing disruptions dented the quarter’s sales further.
However, Abbott exited the fourth quarter of 2022 with better-than-expected earnings and revenues. Excluding COVID testing sales, worldwide Diagnostics sales grew over 11% led by rapid diagnostics. Within EPD, sales increased 8% organically in the fourth quarter led by double-digit growth across several countries.
Meanwhile, the Diabetes Care business continued to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
(You can read the full research report on Abbott Laboratories here >>>)
Shares of Boeing have declined -2.4% over the past year against the Zacks Aerospace - Defense industry’s decline of -7.4%. The company’s 737 MAX program remains a cause of concern in China, thus impacting its expectation of delivery timing and future gradual production rate increases.
Its arch-rival, Airbus, remained quite a step ahead in terms of commercial deliveries during the fourth quarter of 2022. The Russia-Ukraine crisis poses risk for Boeing. However, Boeing remains the largest aircraft manufacturer in the United States, in terms of revenue, orders and deliveries.
Lately, the company has been witnessing solid recovery in its commercial business. The outlook for its defense business also remains optimistic. It holds a strong solvency position in the near term.
(You can read the full research report on Boeing here >>>)
Diageo shares have underperformed the Zacks Beverages - Alcohol industry over the past year (-15.6% vs. -9.5%). The company is facing continued inflationary pressures from increased glass, ocean freight and other transportation costs, and currency headwinds are concerning.
Nevertheless, Diageo’s organic operating margin expansion, productivity savings and favorable currency impact aided Diageo’s first-half fiscal 2023 results. Effective marketing and exceptional commercial execution further aided the results. Price/mix gained from a positive mix due to the robust growth in super-premium-plus brands, particularly scotch, tequila and Chinese white spirits.
DEO’s margin trends were favorable in the first half, thanks to the its premiumization efforts, recovery in markets, pricing actions and supply productivity savings, which mostly offset the cost inflation. The company retained its optimistic view for the medium to long term.
(You can read the full research report on Diageo here >>>)
Other noteworthy reports we are featuring today include Lam Research Corp. and Freeport-McMoRan Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.